Atika Capital Management LLC Cuts Stock Holdings in Immunome, Inc. $IMNM

Atika Capital Management LLC decreased its position in Immunome, Inc. (NASDAQ:IMNM) by 21.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 262,900 shares of the company’s stock after selling 71,441 shares during the quarter. Atika Capital Management LLC’s holdings in Immunome were worth $5,750,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of IMNM. KBC Group NV bought a new stake in Immunome in the first quarter worth about $60,000. BNP Paribas Financial Markets raised its stake in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the period. Strs Ohio bought a new stake in shares of Immunome in the fourth quarter valued at $64,000. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after buying an additional 3,802 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Immunome during the 3rd quarter valued at $76,000. 44.58% of the stock is owned by institutional investors.

Insider Activity

In other news, CFO Max Rosett sold 60,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $18.23, for a total value of $1,093,800.00. Following the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $985,094.51. This represents a 52.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 1,092 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $25.00, for a total value of $27,300.00. Following the completion of the sale, the insider owned 1,092 shares in the company, valued at $27,300. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 472,142 shares of company stock valued at $10,262,648. 7.21% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IMNM shares. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Truist Financial raised their price objective on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and an average target price of $33.17.

Immunome Stock Performance

Shares of IMNM opened at $22.01 on Friday. The firm has a 50 day moving average price of $21.00 and a 200-day moving average price of $21.94. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $27.65. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -9.25 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, equities research analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.